Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.
Type:
Grant
Filed:
February 26, 2016
Date of Patent:
September 10, 2019
Assignee:
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
Type:
Grant
Filed:
May 14, 2018
Date of Patent:
September 3, 2019
Assignee:
BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO
Abstract: A method of treating one or more symptoms associated with underactive bladder in a patient suffering therefrom by administering to the patient a therapeutically effective amount of an acetylcholinesterase inhibitor (AChEI) and an amount of a muscarinic receptor agonist effective to reduce the volume of post void residual in the patient obtained by treatment with the AChEI alone.
Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol.
Abstract: The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) are able to relieve the loss of skeletal muscle strength or function associated with motor neuron diseases.
Abstract: The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ˜95° F. to ˜98.5° F. (˜35° C. to ˜36.7° C.) to mitigate and delay the early onset and progression of fatal disease processes associated with premature aging, such as those characteristic of progeria (Hutchinson-Gilford Progeria Syndrome, HGPS), Wiedemann-Rautenstrauch syndrome (neonatal progeroid syndrome), Werner syndrome, and other rare disorders characterized by premature aging, and to prolong the shortened lifespan of children afflicted with these diseases. Short-term chronic administration of the pharmaceutical treatments to a person suffering from mild concussion may also have value in ameliorating neurological damage/symptoms associated with mild concussion. Chronic administration of the pharmacological treatments may also have value in normal human populations or in high-risk human populations.
Type:
Grant
Filed:
August 1, 2016
Date of Patent:
July 23, 2019
Inventors:
Stephen J. Petti, Samn Raffaniello Petti
Abstract: The invention relates to a new use of diphenyleneiodonium (DPI) as an active substance against parasites of the family Trypanosomatidae, in particular against parasites of the genus Leishmania and Trypanosoma.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
July 16, 2019
Assignee:
Institute of Molecular Genetics, Academy of Sciences of the Czech Republic
Inventors:
Igor Grekov, António Pombinho, Matyá{hacek over (s)} {hacek over (S)}íma, Tetyana Kobets, Petr Bartůn{hacek over (e)}k, Marie Lipoldová
Abstract: The invention relates to the use of a compound of formula (I) or salts thereof for controlling coffee rust, citrus black spot, citrus scab or banana black sigatoka disease, and to corresponding methods.
Abstract: The present invention relates to a concentrated melatonin solution, wherein melatonin is present in a quantity of 10.0% or higher in a substantially water-free carrier mixture of ethanol and a polyethoxylated derivative. The concentrated solution, free of preserving agents, is suitable to prepare injectable sterile compositions for parenteral administration, or formulations for topical or oral administration. The invention also encompasses a method for the preparation of the concentrated solution, as well as the possible benefits of the intravenous infusion of high levels of melatonin as adjuvant therapy in Ebola or Dengue hemorrhagic fever (DHF) or as an anti-oxidant/anti-aging treatment.
Type:
Grant
Filed:
October 12, 2015
Date of Patent:
July 9, 2019
Assignee:
WORPHMED SRL
Inventors:
Paolo Alberto Veronesi, Emanuela Peschechera, Susanna Veronesi
Abstract: Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration. Also provided herein are methods for promoting skin regeneration and wound healing.
Type:
Grant
Filed:
June 27, 2016
Date of Patent:
July 2, 2019
Assignee:
International Stem Cell Corporation
Inventors:
Rodolfo Gonzalez, Maxim Poustovoitov, Russell A. Kern
Abstract: Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.
Type:
Grant
Filed:
September 6, 2017
Date of Patent:
June 25, 2019
Assignee:
Horizon Therapeutics, LLC
Inventors:
Huai-Chueh Chang, Steven S. Pfeiffer, Vasilios H. Iskos, Maki Uragami, Steven Weissman, Andrew Thompson
Abstract: Methods for treating non-systemic deficiencies associated with diabetes using 2-amino substituted nicotinamides or their pharmaceutically acceptable salts.
Abstract: A gelling formulation containing ketamine or a pharmaceutically acceptable salt thereof in water, a poloxamer and one or more pharmaceutically acceptable mucoadhesive agents is provided. Also provided is a method of using the formulation for pain treatment.
Type:
Grant
Filed:
August 30, 2013
Date of Patent:
June 4, 2019
Assignee:
Assistance Publique-Hopitaux de Paris
Inventors:
Vincent Boudy, Annick Tibi, Benoît D'Hayer, Marie-Caroline Husson, Sandrine Graff De Faget
Abstract: The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.
Type:
Grant
Filed:
December 9, 2015
Date of Patent:
June 4, 2019
Inventors:
Xunqiang Wang, Yadong Miu, Min Zhou, Shanchun Wang, Ling Yang, Wei Shi
Abstract: The present invention provides a method of orally treating opiate dependency in a patient in need thereof. The method includes: orally administering an aqueous composition including: tetrahydrocannabinol (THC); one or more aprotic solvents, for example, dimethyl sulfoxide; one or more protic solvents, for example ethanol; and water. Methods of orally reducing or preventing opiate withdrawal, orally reducing or preventing opiate withdrawal symptoms, orally treating post-surgical and chronic pain in a patient are also provided.
Abstract: The present invention relates to a composition for pharmaceutical, nutritional or cosmetic use, suitable to preserve the physiological condition and health of skin and hair and to reestablish their regenerative functions, characterized in that it comprises a mixture of carnitine, caffeine and arginine as active principle, as such or as derivatives, such as pharmacologically acceptable salts. The effect of preserving the physiologic condition and health of skin and hair, and of reestablishing their regenerative functions is mainly achieved through an increase in ATP production by skin and hair cells.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
May 7, 2019
Assignee:
Giuliani S.P.A.
Inventors:
Giammaria Giuliani, Anna Benedusi, Barbara Marzani, Antonio Mascolo, Antonio Limitone
Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
Type:
Grant
Filed:
December 16, 2016
Date of Patent:
April 30, 2019
Assignee:
BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Type:
Grant
Filed:
April 24, 2014
Date of Patent:
April 23, 2019
Assignee:
Amarin Pharmaceuticals Ireland Limited
Inventors:
Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.
Type:
Grant
Filed:
May 26, 2017
Date of Patent:
April 23, 2019
Assignee:
INSYS DEVELOPMENT COMPANY, INC.
Inventors:
Ning Shan, Rajesh R. Wakaskar, Edwin A. Baldwin, Andrew B. Schlinkert, Min Wu, Ningxin Yan
Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
April 16, 2019
Assignee:
Thomas Jefferson University
Inventors:
Davide Trotti, Piera Pasinelli, Michael R. Jablonski